These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 12749725)

  • 1. Implications of genetic testing in the management of colorectal cancer.
    Stoehlmacher J; Lenz HJ
    Am J Pharmacogenomics; 2003; 3(2):73-88. PubMed ID: 12749725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tailored chemotherapy for colorectal cancer: a new approach to therapy.
    Iqbal S; Stoehlmacher J; Lenz HJ
    Cancer Invest; 2004; 22(5):762-73. PubMed ID: 15581057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between mRNA expression of chemotherapy-related genes and clinicopathological features in colorectal cancer: A large-scale population analysis.
    Shimamoto Y; Nukatsuka M; Takechi T; Fukushima M
    Int J Mol Med; 2016 Feb; 37(2):319-28. PubMed ID: 26676887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics and biomarkers in colorectal cancer.
    Strimpakos AS; Syrigos KN; Saif MW
    Pharmacogenomics J; 2009 Jun; 9(3):147-60. PubMed ID: 19381163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotype-based therapeutic approach for colorectal cancer: state of the art and future perspectives.
    Fogli S; Caraglia M
    Expert Opin Pharmacother; 2009 May; 10(7):1095-108. PubMed ID: 19405786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
    Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics of colorectal cancer.
    Marsh S
    Expert Opin Pharmacother; 2005 Dec; 6(15):2607-16. PubMed ID: 16316300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational selection of predictive pharmacogenomics test for the Fluoropyrimidine/Oxaliplatin based therapy.
    Di Francia R; De Lucia L; Di Paolo M; Di Martino S; Del Pup L; De Monaco A; Lleshi A; Berretta M
    Eur Rev Med Pharmacol Sci; 2015 Nov; 19(22):4443-54. PubMed ID: 26636535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomics in colorectal carcinomas: future perspectives in personalized therapy.
    Russo A; Corsale S; Cammareri P; Agnese V; Cascio S; Di Fede G; Macaluso M; Bazan V
    J Cell Physiol; 2005 Sep; 204(3):742-9. PubMed ID: 15828025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetic aspects in treatment of colorectal cancer--an update.
    Stoehlmacher J; Goekkurt E; Lenz HJ
    Pharmacogenomics; 2003 Nov; 4(6):767-77. PubMed ID: 14596640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?
    Koopman M; Venderbosch S; Nagtegaal ID; van Krieken JH; Punt CJ
    Eur J Cancer; 2009 Jul; 45(11):1935-49. PubMed ID: 19473832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular determinants of efficacy for 5-FU-based treatments in advanced colorectal cancer: mRNA expression for 18 chemotherapy-related genes.
    Gustavsson B; Kaiser C; Carlsson G; Wettergren Y; Odin E; Lindskog EB; Niyikiza C; Ma D
    Int J Cancer; 2009 Mar; 124(5):1220-6. PubMed ID: 19051292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenomics in colorectal cancer: the first step for individualized-therapy.
    Bandrés E; Zárate R; Ramirez N; Abajo A; Bitarte N; Garíia-Foncillas J
    World J Gastroenterol; 2007 Nov; 13(44):5888-901. PubMed ID: 17990354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.
    Koopman M; Venderbosch S; van Tinteren H; Ligtenberg MJ; Nagtegaal I; Van Krieken JH; Punt CJ
    Eur J Cancer; 2009 Jul; 45(11):1999-2006. PubMed ID: 19457654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current status of adjuvant chemotherapy for colorectal cancer. Can molecular markers play a role in predicting prognosis?
    O'Connell MJ; Schaid DJ; Ganju V; Cunningham J; Kovach JS; Thibodeau SN
    Cancer; 1992 Sep; 70(6 Suppl):1732-9. PubMed ID: 1516028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacogenetics and tumor sensitivity of antineoplastic agents. Application to colorectal cancer].
    Milano G
    Rev Prat; 2008 May; 58(10):1056-9. PubMed ID: 18652401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer.
    Nobili S; Napoli C; Landini I; Morganti M; Cianchi F; Valanzano R; Tonelli F; Cortesini C; Mazzei T; Mini E
    Int J Cancer; 2011 Apr; 128(8):1935-45. PubMed ID: 20560137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics in cancer chemotherapy: balancing toxicity and response.
    Donnelly JG
    Ther Drug Monit; 2004 Apr; 26(2):231-5. PubMed ID: 15228171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy.
    O'Dwyer PJ; Catalano RB
    J Clin Oncol; 2006 Oct; 24(28):4534-8. PubMed ID: 17008691
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.